Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Smith & Nephew Buys Indian Trauma Business to Spur Growth

Smith & Nephew Plc, Europe’s biggest maker of artificial hips and knees, said it will buy an Indian trauma business and start a share-buyback program after first-quarter earnings missed analysts’ estimates.

Trading profit, which excludes reorganization and acquisition costs, declined to $241 million from $252 million a year earlier, the U.K.’s biggest medical-device maker said today in a statement. Excluding divestments and currency effects, trading profit was unchanged. Earnings excluding some items were 18.5 cents a share, missing the 19-cent average estimate of 11 analysts surveyed by Bloomberg.

Smith & Nephew said it plans to spend $300 million repurchasing shares and also agreed to acquire Adler Mediequip Private Ltd., and the brands and assets of Sushrut Surgicals Private Ltd. The U.K. company has said it wants to expand in wound-care and minimally invasive surgery and emerging markets to offset lower European sales. The company still expects profitability will decline this year.

“We will continue to invest in our growth products, franchises and geographies and maintain adequate headroom for further significant acquisitions,” Chief Executive Officer Olivier Bohuon said in the statement.

Price Tag

The acquisitions in India together with the purchase of the Brazilian distribution business Pro Cirurgia Especializada on May 2 totaled about $70 million, Smith & Nephew said.

Smith & Nephew closed up 1.7 percent to 749 pence in London, giving the company a market value of 6.79 billion pounds ($10.5 billion).

Revenue was unchanged at $1.08 billion, matching the average estimate of 11 analysts surveyed by Bloomberg. Excluding currency effects and the absence of the biologics and clinical therapies business, which was spun off in May 2012 as Bioventus, sales rose 1 percent.

Revenue for Advanced Surgical Devices, which includes implants, sports medicine and trauma, declined to $760 million from $839 million a year earlier and dropped 2 percent when excluding currency effects and acquisitions and disposals. On that basis, sales at the Advanced Wound Management business during the quarter advanced 12 percent to $315 million.

Sales from hip and knee implant franchises both fell 6 percent during the quarter. By comparison, Zimmer Holdings Inc. reported unchanged knee implant sales and a 2 percent decline in hip sales during the quarter. Sales from sports medicine joint repair and trauma both improved during the quarter, up 4 percent and 8 percent respectively, the company said.

“Despite the weaker hip and knee growth, Smith & Nephew delivered on the market’s profit expectations, demonstrating some of the efficiency improvement progress,” Ingeborg Oie, an analyst with Jefferies LLC, wrote in a note to investors.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.